

103 Rec'd PCT/PTO 05 DEC 2005

PCT #9



Attorney Docket: 26465U
Date: December 5, 2005

103 Rec'd PCT/PTO 05 DEC 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
LOOS

Art Unit: Unknown
Examiner: Unknown

Serial No.: 10/518,413

Filed: December 3, 2004

Title: **EXPRESSING CARCINOMAS AND METASTASES**

TRANSMITTAL LETTER

Commissioner of Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:


Submitted herewith for filing in the U.S. Patent and Trademark Office is the following:

- 1) Supplemental Information Disclosure Statement;
- 2) Supplemental PTO Form-1449 with 1 cited Reference;
- 3) Copy of the 1 cited Reference.

The Commissioner is hereby authorized to charge any deficiency or credit any excess to Deposit Account No. 14-0112.

Respectfully submitted,
NATH & ASSOCIATES PLLC

By:


Gary M. Nath, Reg. No. 26,965
Tanya E. Harkins, Reg. No. 52,993
Customer No. 20529

NATH & ASSOCIATES PLLC
1030 15th St., N.W., 6th Fl.
Washington, D.C. 20005
GMN/TH/LE (SIDS)



Attorney Docket: 26465U
Date: December 5, 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
LOOS

Art Unit: Unknown
Examiner: Unknown

Serial No.: 10/518,413

Filed: December 3, 2004

Title: **EXPRESSING CARCINOMAS AND METASTASES**

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

An Information Disclosure Statement is submitted herewith pursuant to 37 C.F.R. 1.97-1.98. Please note the following particulars: [NOTE: One only of items a, b, c, and d must be checked.]

[XXX] a. The enclosed statement is being filed within three months of the filing date of a national application, or within three months of the date of entry into the national stage as set forth in 37 C.F.R. 1.491 in an international application, or before the mailing date of a first Office Action on the merits, whichever event occurs last.

[] b. The enclosed statement is being filed after a first action on the merits but before the mailing date of a final action under 37 C.F.R. 1.113, or a notice of allowance under 37 C.F.R. 1.311.

The enclosed statement is accompanied by [check one]:

[] i. a certification in part (e) below as specified in 37 C.F.R. 1.97(e), or

[] ii. a check in the amount required by 37 C.F.R. 1.17(p).

[] c. The enclosed statement is being filed after the mailing date of a final action under 37 C.F.R. 1.113, or a notice of allowance under 37 C.F.R. 1.311, but before payment of the issue fee.

[] Certification report(e) below; and

[] a check in the amount as required by 1.17(p).

[] d. The enclosed statement is being filed pursuant to 37 C.F.R. 1.97(i), for placement in the file.

[] e. Certification [Check one] [Certification is required only if box (b)(i) or box (c) is checked.]

[] I hereby certify that each item of information contained in the enclosed Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement,

or

[] I hereby certify that no item of information in the enclosed Information Disclosure Statement herewith was cited in a communication from a foreign patent office in a counterpart foreign application, or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

or

[] Appropriate certification is attached.

[XXX] f. If no check is enclosed and a fee is due in connection with this communication or if the check enclosed is insufficient, the Commissioner is authorized to charge any fee or additional fee due in connection with this communication to Deposit Account No. 14-0112.

[XXX] g. Copies of the documents are attached herewith with a completed Form PTO-1449.

or

[] Copies of the documents are not attached as allowed under CFR 1.98(d)(1)(2). The earlier application is identified as:

and/or


[] Copies of US Patents/Publications not attached as allowed in Official Gazette Aug. 5, 2003/ Vol. 1273, no. 1.

The Examiner is respectfully requested to cite the documents listed on the attached Form PTO-1449 in the next Office Action. In so doing, the Examiner is respectfully requested to initial in the space adjacent to the listing of each document on the Form PTO-1449, and return a copy of the initialed Form PTO-1449 with the next communication to Applicants, to confirm that these documents have been considered by the Examiner and made of record in this application.

If the Examiner has any questions or wishes to discuss this application, kindly telephone the undersigned at the below-listed number.

Respectfully submitted,
NATH & ASSOCIATES PLLC

By:



Gary M. Nath, Reg. No. 26,965
Tanya E. Harkins, Reg. No. 52,993
Customer No. 20529

NATH & ASSOCIATES PLLC
1030 15th St., N.W., 6th Fl.
Washington, D.C. 20005
GMN/TH/LE (SIDS.STATEMENT)



U.S. Pat. & Tm. Off. 05 DEC 2005

Page 1 of 1

FORM PTO-1449 <u>INFORMATION DISCLOSURE</u> <u>CITATION</u>		Attorney Docket: 26465U		Serial No.: 10/518,413	
		In re Application of: LOOS		Filed: December 3, 2004	
		Art Unit: Unknown		Examiner: Unknown	
U.S. PATENT DOCUMENTS					
Examiner Initial		Document Number	Issue Date	Name	Filing Date
	A1				
	A2				
	A3				
	A4				
FOREIGN PATENT DOCUMENTS					
		Document Number	Date	Country	Translation
	A5				
	A6				
	A7				
	A8				
OTHER (Including Author, Title, Date, Pertinent Pages, etc.)					
	A9	Tanosaki, S., et al., "Effect of ligands of nuclear hormone receptors on sodium/iodide symporter expression and activity in breast cancer cells", <u>Breast Cancer Research and Treatment</u> , vol. 79, pages 335-345, (2003).			
	A10				
	A11				
	A12				
Examiner			Date Considered		
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP ' 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.					